FDA Refuses To Review Acorda's MS Drug
March 31, 2009 at 13:18 PM EDT
The Food and Drug Administration refused to review Acorda Therapeutics Inc.'s (Nasdaq: ACOR) multiple sclerosis treatment fampridine citing format issues. Shares of the biopharmaceutical plummeted $4.70 to $20.20.
